Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G. Gertz MA, et al. Among authors: comenzo rl. Blood. 2023 Oct 5;142(14):1208-1218. doi: 10.1182/blood.2022019406. Blood. 2023. PMID: 37366170 Free PMC article. Clinical Trial.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. Sanchorawala V, et al. Among authors: comenzo rl. Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26. Blood. 2017. PMID: 28550039 Free PMC article. Clinical Trial.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Palladini G, et al. Among authors: comenzo rl. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. Blood. 2020. PMID: 32244252 Free PMC article. Clinical Trial.
Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).
Dispenzieri A, Merlini G, Comenzo RL. Dispenzieri A, et al. Among authors: comenzo rl. Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):6-11. doi: 10.1016/j.bbmt.2007.10.026. Biol Blood Marrow Transplant. 2008. PMID: 18162215 Free article. Review.
Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego).
Dispenzieri A, Merlini G, Comenzo RL. Dispenzieri A, et al. Among authors: comenzo rl. Biol Blood Marrow Transplant. 2008 Jan;14(Supplement 1):6-11. doi: 10.1016/j.bbmt.2007.10.026. Biol Blood Marrow Transplant. 2008. PMID: 19122741 Free PMC article. No abstract available.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. Palladini G, et al. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22. J Clin Oncol. 2012. PMID: 23091105
Immunoglobulin light chain amyloidosis.
Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Merlini G, et al. Among authors: comenzo rl. Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18. Expert Rev Hematol. 2014. PMID: 24350907 Review.
180 results